Introduction {#Sec1}
============

Coping with breast cancer, its treatment, and consequences can be stressful and, if not successful, can result in clinically relevant levels of psychological distress. Twenty-five to fifty percent of all cancer patients experience clinically relevant distress, which has been associated with lower treatment adherence, poorer clinical and psychosocial outcomes, and less satisfaction with medical care \[[@CR1]--[@CR6]\]. Breast cancer patients' distress levels may rise at different stages throughout the disease trajectory \[[@CR7]--[@CR11]\]. For example, some patients experience clinical distress just postdiagnosis, while others are mostly affected after treatment due to the discontinuation of regular contacts with medical specialists and/or to treatment-induced side effects \[[@CR12], [@CR13]\]. Fortunately, for most patients, distress levels tend to return to subclinical levels with time \[[@CR7], [@CR8], [@CR10], [@CR11], [@CR14], [@CR15]\]. However, a subgroup of patients develops enduring, heightened, distress. Enduring clinical distress within 8 months after surgery predicts poorer psychosocial outcomes 6 years later \[[@CR6]\]. Thus, clinicians and cancer nurses ought to be especially watchful of patients at risk for developing enduring distress.

In order to ensure timely detection, discussion, and treatment of distress, the National Comprehensive Cancer Center recommends use of an ultrashort screening tool, the Distress Thermometer, and accompanying Problem List \[[@CR16]\]. This self-report questionnaire assesses cancer patients' distress level and distress-related problems, along with their wish for referral to professional care. The Distress Thermometer is currently used in various countries worldwide, including the United States, the United Kingdom, Japan, and China (see \[[@CR17]\] for an overview). Given its common use, many oncologists and cancer nurses would benefit from knowing how many and which women with breast cancer are most likely to develop enduring clinical distress as measured with the Distress Thermometer. However, while a number of cross-sectional studies used the screening tool to examine distress among women with breast cancer \[[@CR18]--[@CR29]\], only one examined continuing distress, during the treatment phase \[[@CR10]\]. Thus, more longitudinal research is needed.

In the present study we aimed to extend current insights using the Distress Thermometer to investigate which women are most likely to experience enduring distress after treatment for breast cancer. More specifically, enduring distress was defined as elevated distress levels at two points in time: 6 months postdiagnosis, around the completion of adjuvant therapy, and 9 months later, when women, generally, have reached the early survivorship phase \[[@CR8]\]. We investigated the prevalence of enduring clinical distress, the prevalence of women's wish for referral, and sociodemographic, clinical, and psychosocial predictors of enduring clinical distress.

Methods {#Sec2}
=======

Participants and design {#Sec3}
-----------------------

This study had a prospective, multicenter, observational design. Women with primary breast cancer who had been diagnosed up to 6 months earlier in one of nine hospitals in the Netherlands (i.e., six academic hospitals, two community hospitals, and one comprehensive cancer center) were eligible for the study, regardless of type of treatment. Patients were excluded if they were younger than 18 years, not literate in Dutch, or had a prognosis of 3 months or less. To minimize patient burden, participating centers could also exclude patients who were already participating in a concurrent study. Inclusion took place between March 2011 and 2013.

Participants completed a self-report questionnaire at two points in time: 6 months (time window 5--7 months) and 15 months (time window 14--16 months) postdiagnosis. Medical data were retrieved via chart reviews. Because the study was observational in nature, following Dutch regulations and guidelines regarding ethics review, it did not require formal review by the institutional review boards of the participating centers.

Procedure {#Sec4}
---------

Eligible patients with breast cancer were identified by their oncologist, nurse practitioner, or cancer nurse during a hospital visit. The health care provider informed the patient about the study and asked whether she would consider participation. The investigator subsequently invited interested patients to participate by e-mail or telephone. Participants could choose between a web-based questionnaire accessible through e-mail or a paper questionnaire sent by regular mail with a stamped return envelope. Formal agreement to participation involved signing an informed consent form. If necessary, patients received reminders after 2 and 4 weeks by e-mail or telephone.

Outcome measures {#Sec5}
----------------

Psychosocial distress, distress-related problems, and wish for referral were assessed at both assessment points with the validated Dutch version of the Distress Thermometer, accompanied by the Problem List \[[@CR16], [@CR30], [@CR31]\]. The Thermometer measures the *level of distress* in the past week with a single item (score 0--10). In the introduction to the questionnaire, we emphasized that it was a measure of distress related to breast cancer and its treatment. Based on the Dutch validation study \[[@CR30]\] (see also \[[@CR31]\]), a score of ≥5 was used to identify women with clinically relevant levels of distress.

The Dutch version of the Problem List identifies 47 *problems* across the practical, family/social, emotional, religious/spiritual, and physical domains (response categories for the presence of each problem: yes/no). *Wish for referral* is assessed with one question. Patients are asked whether they would like to talk with a professional about their problems (response categories yes/maybe/no). In the current study, the response category 'not applicable' was added for patients who did not report any problems. We recoded the response categories to 'yes or maybe' versus 'no or not applicable' to enable comparability with other studies.

Sociodemographic predictors {#Sec6}
---------------------------

Age at diagnosis, nationality, educational level, living situation, and employment status were assessed by self-report 6 months postdiagnosis.

Clinical predictors {#Sec7}
-------------------

Type of breast cancer, cancer stage (via pTNM-classification), types of treatments, and presence of recurrence (yes/no) were retrieved from medical chart reviews. Previous use of psychosocial services (yes/no) and number of comorbid conditions (adapted from \[[@CR32]\]) were assessed by self-report 6 months postdiagnosis.

Psychosocial predictors {#Sec8}
-----------------------

We decided a priori to include the three most prevalent *distress*-*related problems* reported at 6 months postdiagnosis, as assessed with the previously described Problem List, as psychosocial predictors. In addition, social support, cancer worry, present life satisfaction, and neuroticism, as measured 6 months postdiagnosis, were included (variables selected on the basis of \[[@CR8], [@CR33]--[@CR39]\]).

*Social support* was measured with the emotional/informational support subscale of the Medical Outcomes Study Social Support Survey (8 items, range 1 'support not available' to 5 'support always available', α = .96 based on data from this study) \[[@CR40], [@CR41]\].

*Lifesatisfaction* was measured with a single item that asked patients about their present satisfaction with life as a whole (range 0--10) \[[@CR42]\].

*Frequency of cancer worry* was assessed with a single item (range 1 'never' to 4 'always') (adapted from \[[@CR43]\]).

*Neuroticism* was measured with a subscale of the Eysenck Personality Questionnaire (12 y/n items) \[[@CR44], [@CR45]\].

Data analyses {#Sec9}
-------------

Prior to the main analyses, we first examined missing data patterns with separate variance *t*-tests, cross tabulations, a tabulated pattern table and Little's missing completely at random test with a *χ*^2^ statistic (*p* \< 0.05). The results did not indicate substantial influence of the missing data on the results. Thus, we assumed that these data were missing at random. The percentage of missing values for all the variables ranged from 0 % to 8 %. The data were subsequently multiple imputed by fully conditional specification with a maximum of five iterations \[[@CR46], [@CR47]\]. Secondly, we examined the correlations between distress and the psychosocial measures at 6 months postdiagnosis with Spearman's rank correlation coefficients \[[@CR48]\] to ascertain the degree of interdependence. The correlations ranged from −0.15 for the correlation with social support to −0.52 for the correlation with life satisfaction, indicating low to moderate associations. We then proceeded to the main analyses.

The prevalence of enduring clinical distress, distress-related problems, and a wish for referral was examined with descriptive analyses. Associations between predictors and enduring clinical distress were investigated twice. We first performed univariate logistical regression analyses (significance level *p* \< 0.10), followed by a multivariate analysis with the predictors that were found to be significant in the univariate analyses (significance level for the multivariate analysis *p* \< 0.05). We then examined the associations again with Generalized Estimating Equations, taking into account the within-subject correlations. The same predictors were found to be significant in the multivariate analysis, with comparable parameters and standard errors. Therefore, only the results of the logistical regression analyses are reported, in odds ratios (OR). All of the analyses were conducted with SPSS version 21 for Windows.

Results {#Sec10}
=======

Sample {#Sec11}
------

In total, 1353 women with breast cancer were assessed for study eligibility. Of these women, 1263 were eligible, and 1012 agreed to participate (80.1 % of the eligible women). The current analyses were restricted to the 746 women who completed both the first and second questionnaires at 6 and 15 months postdiagnosis (73.7 % of the participants) (see Fig. [1](#Fig1){ref-type="fig"}). The majority of the women was diagnosed with stage 1 or 2 invasive breast cancer, and was treated with lumpectomy and radiotherapy. Over 60 % had one or more comorbid conditions (Table [1](#Tab1){ref-type="table"}). Of the participants, 45.7 % chose to receive a paper rather than a web-based questionnaire.Fig. 1FlowchartTable 1Sample Characteristics (*n* = 746)CharacteristicsTotal sample*Sociodemographic factors* Age at diagnosis (median, range)58 (24--83) Nationality (*n*, %)  Dutch only716 (96.0)  Dutch and other or other only30 (4.0) Educational level (*n*, %)^a^  Low346 (46.4)  Intermediate185 (24.8)  High215 (28.8) Living situation (*n*, %)  With partner383 (51.3)  With partner and child(ren)192 (25.7)  With child(ren)34 (4.6)  Alone127 (17.0)  Other10 (1.3) Employment status (*n*, %)  Paid work278 (37.3)  Homemaker141 (18.9)  Retired197 (26.4)  No work or unpaid56 (7.5)  (Partly) Work-disabled due to breast cancer74 (9.9)*Clinical factors* Type of breast cancer (*n*, %)  Ductal carcinoma in situ (DCIS)104 (13.9)  Invasive and DCIS57 (7.6)  Invasive585 (78.4) Cancer stage at diagnosis (*n*, %)  TIS: carcinoma in situ104 (13.9)  Invasive early stage (T1/T2)621 (83.2)  Invasive late stage (T3/T4)21 (2.8) Type of surgery (*n*, %)  Lumpectomy630 (84.5)  Mastectomy105 (14.1)  Lumpectomy and mastectomy9 (1.2)  No lumpectomy or mastectomy2 (0.3) Radio- and/or chemotherapy (*n*, %)  Radiotherapy only470 (63.0)  Chemotherapy only24 (3.2)  Radio- and chemotherapy198 (26.5)  No radio- or chemotherapy54 (7.2) Other types of treatment (*n*, %; yes/no)  Hormonal258 (34.6)  Immunotherapy32 (4.3) Recurrence (*n*, %)  No731 (98.0)  Yes15 (2.0) Previous use of psychosocial services (*n*, %)  No578 (77.5)  Yes168 (22.5) Comorbidity (*n*, %)  0 comorbid conditions282 (37.8)  1 comorbid condition231 (31.0)  2 or more comorbid conditions233 (31.2)*Psychosocial factors 6 months postdiagnosis* Social support (median, range)4.25 (1--5) Life satisfaction (median, range)7 (0--10) Cancer worry (median, range)3 (1--4) Neuroticism (median, range)2 (0--12)

Participants did not differ significantly in age (groups based on median split, *p* \> 0.10) or cancer stage from nonrespondents, i.e., women who were approached by the researcher but who could not be reached, declined to participate, or who did not return both questionnaires (*χ*^2^, *p* \> 0.10). Furthermore, respondents who only completed the questionnaire at 6 months postdiagnosis (*n* = 111) did not differ significantly in age (*χ*^2^, *p* \> 0.10), cancer stage (*χ*^2^, *p* \> 0.10), or distress scores (*t*-tests, *p* \> 0.10) from the respondents who completed the questionnaires at both 6 and 15 months postdiagnosis (*n* = 746). We did not collect background data from patients who did not want to be approached about the study (*n* = 74).

Prevalence of enduring clinical distress, distress-related problems, and wish for referral {#Sec12}
------------------------------------------------------------------------------------------

Forty-one percent of the patients experienced clinical distress 6 months postdiagnosis, and 32 % 15 months postdiagnosis. Twenty-two percent of the patients experienced enduring clinical distress at 6 and 15 months postdiagnosis (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). The most frequently reported problems 6 months postdiagnosis were fatigue, lack of physical fitness, lack of muscle strength, sleep problems, and concentration problems for both clinically and nonclinically distressed patients. Fifteen months postdiagnosis fatigue, lack of physical fitness, and sleep problems were still most frequently reported (Table [3](#Tab3){ref-type="table"}). Ten percent of the patients with enduring clinical distress had a wish for referral 15 months postdiagnosis. In addition, 17 % of patients without enduring clinical distress also had a wish for referral (Table [4](#Tab4){ref-type="table"}).Table 2Prevalence of enduring clinical distress (score ≥5 at both time points)Distress 15 months postdiagnosis (*n*, %)TotalScore \<5Score ≥5Distress 6 months postdiagnosis (*n*, %)Score \<5367 (49.2)74 (9.9)441 (59.1)Score ≥5142 (19.0)163 (21.8)305 (40.9)Total509 (68.2)237 (31.7)746 (100.0)Fig. 2Prevalence of distress 6 and 15 months postdiagnosis (*n* = 746)Table 3Top 10 distress-related problems 6 and 15 months postdiagnosisRank6 months postdiagnosis15 months postdiagnosisDistress score \<5 (%)Distress score ≥5 (%)Distress score \<5 (%)Distress score ≥5 (%)1Fatigue(33.2)Fatigue(35.3)Fatigue(28.3)Fatigue(24.6)2Lack of physical fitness(27.7)Lack of physical fitness(33.5)Lack of physical fitness(23.6)Lack of physical fitness(22.3)3Lack of muscle strength(18.6)Lack of muscle strength(26.7)Sleep problems(21.1)Sleep problems(19.7)4Sleep problems(18.3)Sleep problems(24.8)Memory problems(18.2)Concentration problems(18.8)5Concentration problems(17.4)Concentration problems(23.9)Concentration problems(17.7)Memory problems(18.4)6Emotional control(16.1)Housekeeping(22.3)Lack of muscle strength(16.6)Lack of muscle strength(18.4)7Memory problems(15.7)Emotional control(22.2)Tingling in hands/feet(14.9)Emotional control(18.2)8Tension/nervousness(15.2)Tension/nervousness(22.0)Weight change(14.8)Tension/nervousness(18.0)9Skin dry/itchy(14.2)Pain(21.1)Emotional control(14.5)Pain(16.5)10Weight change(13.4)Daily activities(19.6)Tension/nervousness(13.8)Fears(15.4)Table 4Prevalence of wish for referralWish for referral 15 months postdiagnosis (*n*, %)TotalNoYes or maybeEnduring clinical distress (n, %)No456 (61.1)127 (17.0)583 (78.2)Yes89 (11.9)74 (9.9)163 (21.8)Total545 (73.1)201 (26.9)746 (100.0)

Predictors of enduring clinical distress {#Sec13}
----------------------------------------

Of the sociodemographic factors, younger age (OR = 0.96), living with a partner and children (OR = 1.75) or only with children (OR = 2.57), and having a paid job compared to being retired (OR = 0.43) predicted enduring clinical distress in the univariate analyses (*p* \< 0.10). Furthermore, having a mastectomy compared to a lumpectomy (OR = 1.72), having chemotherapy (OR = 2.47) or radio- and chemotherapy (OR = 1.85) compared to radiotherapy only, having received psychosocial services before the breast cancer diagnosis (OR = 2.03), and having two or more comorbid conditions (OR = 1.51) were significant clinical predictors of enduring clinical distress in these analyses. Additionally, all the seven psychosocial factors, namely fatigue (OR = 4.81), lacking physical fitness (OR = 3.12), lacking muscle strength (OR = 4.16), experiencing a low level of social support (OR = 0.75), a low level of life satisfaction (OR = 0.60), more frequent cancer worry (OR = 2.23), and more neuroticism (OR = 1.23) were identified as univariate significant predictors of enduring clinical distress.

In the multivariate analysis lacking muscle strength (OR = 1.82, 95 % CI 1.12--2.98), experience of a low level of life satisfaction (OR = 0.77, 95 % CI 0.67--0.89), more frequent cancer worry (OR = 1.40, 95 % CI 1.05--1.89), and neuroticism (OR = 1.09, 95 % CI 1.00--1.18) remained significant (Table [5](#Tab5){ref-type="table"}). The variance explained (*R*^2^ Nagelkerke \[[@CR49]\]) across imputed datasets was, on average, 30 %.Table 5Predictors of enduring clinical distressPredictor^a^Multivariate analysis\
OR (95 % CI)^b,\ c^*Sociodemographic factors* Age at diagnosis0.99 (0.96--1.03) Living situation  With partner1.00 (reference)  With partner and child(ren)1.33 (0.72--2.43)  With child(dren)2.38 (0.95--5.95)  Alone1.09 (0.58--2.04)  Other2.58 (0.44--15.24) Employment status  Paid work1.00 (reference)  Homemaker0.73 (0.39--1.38)  Retired0.72 (0.33--1.57)  No work or unpaid1.19 (0.47--3.04)  (Partly) Work-disabled due to breast cancer0.69 (0.31--1.55)*Clinical factors* Type of surgery^d^  Lumpectomy1.00 (reference)  Mastectomy1.12 (0.54--2.30)  Lumpectomy and mastectomy1.08 (0.15--7.67) Radio- and or chemotherapy  Radiotherapy only1.00 (reference)  Chemotherapy only1.04 (0.29--3.76)  Radio- and chemotherapy1.25 (0.76--2.05)  No radio- or chemotherapy1.58 (0.61--4.12) Previous use of psychosocial services  No1.00 (reference)  Yes1.19 (0.74--1.92) Comorbidity  0 comorbid conditions1.00 (reference)  1 comorbid condition1.19 (0.71--2.02)  2 or more comorbid conditions1.69 (0.98--2.93)*Psychosocial factors* Fatigue  No1.00 (reference)  Yes1.31 (0.67--2.56) Lack of physical fitness  No1.00 (reference)  Yes1.75 (0.90--3.38) Lack of muscle strength  No1.00 (reference)  Yes**1.82 (1.12--2.98)** Social support0.96 (0.77--1.19) Life satisfaction**0.77 (0.67--0.89)** Cancer worry**1.40 (1.05--1.89)** Neuroticism**1.09 (1.00--1.18)**^a^Predictors are measured at 6 months postdiagnosis. Women with enduring distress are compared to those without enduring distress^b^OR = odds ratio; CI = confidence interval^c^Printed in bold: multivariate analysis *p* \< 0.05^d^Patients who did not receive surgery (*n* = 2) were excluded from the analyses

Discussion {#Sec14}
==========

While a number of studies have examined distress among women with breast cancer, insight into enduring distress, and predictors of enduring distress is still scarce, especially with regard to enduring distress as measured with the Distress Thermometer. In this longitudinal, nationwide, study we established that one in five patients with breast cancer reported clinical distress at 6 and 15 months postdiagnosis, as measured with the Distress Thermometer. Fatigue and lack of physical fitness were the most frequently reported problems at both time points. Ten percent of the participants with enduring clinical distress had a wish for referral.

The prevalence of distress in the only other, Danish, study that examined persistent distress with the Distress Thermometer was only 8 % within the first 8 months postdiagnosis (*n* = 323) \[[@CR10]\]. The lower prevalence in that study can be explained by the higher cut-off point of seven used. We found a comparable percentage (7 %) when we applied a cut-off point of seven to our data to enable comparison. The choice of a validated cut-off score depends on the purpose of screening \[[@CR50]\], and this may differ between countries. In general, a higher score implies higher sensitivity but also a higher percentage of false negatives.

A remarkable finding was that the percentage of patients with a wish for referral in the group with enduring clinical distress was lower than in the group without enduring clinical distress (10 vs. 17 %). This is in contrast with the findings of previous, cross-sectional, studies that examined distress. The wish for a referral in these studies was, generally, more prevalent among women with a clinical level of distress than in women without distress (e.g., \[[@CR21]\]). Our finding might indicate that a portion of the patients with enduring clinical distress has already been identified and referred through effective screening. Unfortunately, we did not assess use of psychosocial services up to 15 months, which would allow testing of this hypothesis.

Depending on service availability, all wishes for a referral deserve further inquiry. The high percentage of patients with enduring clinical distress without a wish for referral raises the question if and how a practitioner should proceed in that situation. Minimally, we would recommend that providers inform patients about the health risks associated with enduring clinical distress \[[@CR6]\], and about those services that are available to manage and hopefully resolve such distress. Providers should also explore the patients' reason for their response. Some patients may already receive professional support or may prefer to deal with their distress on their own, perhaps with help from their informal network \[[@CR51]--[@CR54]\]. In the end, the wish to accept a referral is up to the patients. However, there may also be patients who misperceive their distress as not severe enough to ask for help, and who might accept help after being otherwise informed \[[@CR53]\].

While younger age, having a partner, having less education, and having chemotherapy and not radiotherapy, were previously found to be associated with enduring clinical distress \[[@CR10]\], none of these factors were significant predictors in our multivariate model. Based on our results, psychosocial variables appear more relevant than clinical variables to identify patients at risk of developing enduring clinical distress. Our analyses identified lack of muscle strength, a low level of life satisfaction, and more frequent cancer worry as significant predictors, independent of one's level of neuroticism (see also \[[@CR6], [@CR52]\]). To our knowledge, this study is the first to demonstrate that these factors are of value in predicting enduring clinical distress of women with breast cancer. Based on our and previous findings, addition of cancer worry to future versions of the Problem List warrants further research attention (e.g., \[[@CR55]\]; see also \[[@CR37]\]).

Life satisfaction or happiness is increasingly recognized as a vital contributor to health, (partly) independent of negative affect (e.g., \[[@CR56], [@CR57]\]). It may be important to consider during the development of interventions to diminish distress. Some patients may prefer such a positive approach. A recent study demonstrated that the level of happiness experienced by breast cancer patients can, to a certain degree, be enhanced through intervention \[[@CR35]\].

A study limitation is that we were not able to gather information about patients who declined to be approached for the study. Therefore, we could not establish our sample's representativeness in that regard. We did establish that there was no indication of a sample bias resulting from loss to follow-up. Another limitation is the large proportion of participants recruited at radiotherapy departments. As a consequence, patients with breast cancer who do not receive radiotherapy, though a minority, were underrepresented in our sample. To give an impression, a previous study based on data from a Dutch population-based, regional cancer registry, indicated that 17 % of the women with breast cancer received systemic therapy without radiotherapy in the period 2002--2006 \[[@CR58]\]. Finally, our study design did not allow us to make a distinction between women with breast cancer who experienced clinical distress continuously or intermittently, i.e., at the two assessment points only.

Strengths of the study are its large sample size, the prospective design, and the inclusion of psychosocial predictors that are easy to assess in clinical practice. We were able to use the Distress Thermometer to address two research topics that were recently identified as relevant in an ongoing debate about the usefulness and validity of screening for distress \[[@CR59]\]. First, we investigated the occurrence of enduring clinical distress within a relevant time period \[[@CR7], [@CR11]\]. Second, we identified possible modifiable predictors of enduring clinical distress as targets for future interventions. While some of these predictors were previously found to be associated with distress, their importance in relation to predicting enduring distress had yet to be established. Furthermore, our study is the first to examine how many women with enduring distress would like a wish for a referral to professional care.

We recommend further studies of modifiable psychosocial factors in relation to resilience to distress over time in order to determine whether the occurrence of distress may be prevented even before its first manifestation \[[@CR7], [@CR8], [@CR14]\]. We further suggest that patients' need for help in relation to distress be assessed more comprehensively than with the single question about a wish for referral. A substantial percentage of the patients who do not wish to talk to a professional, may consider use of other support services such as participating in an e-health intervention or support group. Finally, a large percentage of variance in our multivariate model remained unexplained. We recommend investigation of the influence of treatment center variables such as patient volume and waiting time before surgery as relevant predictors of breast cancer patients' distress, in addition to patient-based predictors. Treatment center variables might be important predictors of psychosocial outcomes \[[@CR60]\].

In conclusion, one in five women with breast cancer experiences enduring clinical distress after treatment. In order to ensure timely detection of patients with enduring clinical distress, oncologists and cancer nurses are advised to pay special attention to distressed patients with a lack of muscle strength, as measured by the Distress Thermometer and Problem List. Fatigue is the most frequently reported problem over time, and thus should be routinely assessed and adequately addressed. Developers of distress interventions are advised to target these problems as well as life satisfaction and cancer worry in their program.
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